Related references
Note: Only part of the references are listed.Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases
Sarah Wendel et al.
JOURNAL OF AUTOIMMUNITY (2019)
Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
Sara Sabbagh et al.
BRAIN (2019)
Interferon-signature in idiopathic inflammatory myopathies
Laure Gallay et al.
CURRENT OPINION IN RHEUMATOLOGY (2019)
Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib
Siamak Moghadam-Kia et al.
RHEUMATOLOGY (2019)
JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis
Leandro Ladislau et al.
BRAIN (2018)
Juvenile Idiopathic Inflammatory Myopathies
Adam M. Huber
PEDIATRIC CLINICS OF NORTH AMERICA (2018)
Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment
Drew J. B. Kurtzman et al.
JAMA DERMATOLOGY (2016)
Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
Brittany G. Craiglow et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Pathogenesis of Dermatomyositis: Role of Cytokines and Interferon
Lily Kao et al.
CURRENT RHEUMATOLOGY REPORTS (2011)
Share Paper
